Previous Article | Next Article ![]()
Journal of Clinical Microbiology, November 2001, p. 4193-4195, Vol. 39, No. 11
Institute for Veterinary Bacteriology,
University of Bern, Bern, Switzerland,1 and
Danish Veterinary Laboratory, Copenhagen,
Denmark2
Received 30 November 2001/Returned for modification 29 March
2001/Accepted 3 September 2001
Ninety-six enterococcus isolates from fecal samples of pigs
receiving tylosin as an antimicrobial growth promoter and 59 isolates obtained in the same farms 5 to 6 months after the ban of antimicrobial growth promoters in Switzerland were tested for susceptibility to nine
antimicrobial agents. A clear decrease in resistance to macrolides,
lincosamides, and tetracycline was visible after the ban.
Vancomycin-resistant Enterococcus faecium belonged to
the same clonal lineage as vancomycin-resistant isolates previously isolated from Danish pigs.
A variety of antibiotics are applied
in animal husbandry at subtherapeutical levels as antimicrobial growth
promoters (AGPs). Previous studies have shown that the use of AGPs may
select resistant bacteria among the normal intestinal flora of animals
(2, 3, 6). In some countries, therapeutically important
antimicrobial agents or related substances are licensed for use as
AGPs. For instance, avoparcin, a member of the glycopeptide family, and tylosin, a member of the macrolide family, have been widely used in
Europe as AGPs. These two substances have consequently been associated
with a high prevalence of vancomycin-resistant enterococci (VRE) and of
macrolide-resistant enterococci in the intestinal flora of pigs and
poultry (2, 3, 6, 8). The transmission of bacteria between
animals and humans is not limited to agents of zoonotic diseases.
Therefore, the selection of a reservoir of resistant opportunistic
human pathogens and of possibly transmissible resistance determinants
through the use of AGPs may have undesirable consequences for human
health. For these reasons, and with the noticeable exception of
tylosin, all the antimicrobial agents belonging to substance classes
used for therapeutic treatments in humans (including tetracyclines)
have been forbidden as AGPs since 1972 in Switzerland. For the same
reasons, the use of avoparcin was also forbidden in Switzerland and in
the European Union in February and April 1997, respectively. Finally,
the use of any kind of AGPs was completely forbidden in Switzerland at
the beginning of 1999, with a transitional period for completion of the
ban ending on 30 June 1999.
In order to investigate the short-term effect of the AGP ban on
antimicrobial resistance among fecal enterococci from pigs in
Switzerland, a study was undertaken in farms using tylosin as an AGP
before and after the complete cessation of AGP use. The evolution of
resistance to macrolides, to vancomycin, and to other therapeutic
antimicrobial agents not used as AGPs was examined. After the farmers
were informed of the aim of the study and the procedures to be used,
fecal samples from 16 farms that were still using tylosin as an AGP
shortly before the AGP ban were investigated in a first step (farmers
and feed producers were contacted to verify that tylosin was used
regularly at this time). Samples from 13 of these farms were obtained
and examined again 183 to 287 days later (median, 225 days). These
samples were obtained 153 to 259 days (median, 161 days) after the
final compulsory cessation of AGP use at the end of June 1999. For this purpose, two fresh fecal samples collected by the farmers on the same
day in two different pens were sent immediately to the laboratory, mixed together in equal proportions, and inoculated on selective agar
plates as follows. The fecal samples were homogeneously resuspended in
a 1/5 proportion in brain heart infusion broth (Difco Laboratories, Detroit, Mich.), and approximately 200 µl of this suspension was used
for isolation of enterococci on kanamycin-esculin azide agar (Merck,
Darmstadt, Germany), on KF-streptococcus agar (Merck), and on
Enterococcosel agar (Becton Dickinson Co., Cockeysville, Md.),
following the instructions of the manufacturers. Four to six
enterococcus-like colonies randomly chosen to represent all the
morphologies observed on the plates were further examined for each
sample. For samples with homogeneous colonies, a total of four to six
colonies were randomly selected from the different selective media
used. Esculin-positive, catalase-negative, and gram-positive cocci were
identified at the species level using Rapid ID32 Strep galleries
following instructions of the manufacturer (BioMerieux SA,
Marcy-l'Etoile, France). A total of 96 and 59 Enterococcus
sp. isolates were obtained before and after the AGP ban, respectively
(Table 1). These 155 isolates consisted
of 72 Enterococcus faecium isolates, 63 Enterococcus
hirae isolates, 10 Enterococcus faecalis isolates, 7 Enterococcus gallinarum isolates, 2 Enterococcus
durans isolates, and 1 Enterococcus casseliflavus isolate. Susceptibility testing was performed for all the isolates by
disk diffusion using erythromycin, spiramycin, clindamycin, vancomycin,
penicillin, tetracycline, chloramphenicol, high-level streptomycin, and
high-level gentamicin disks (Sanofi Diagnostics Pasteur,
Marnes-la-Coquette, France) following the NCCLS standard protocols for
enterococci (9). Except for spiramycin and clindamycin, the interpretation criteria used were those of the NCCLS norm (10). For spiramycin (100-µg disks), strains with zone
diameters smaller than 16 mm, between 16 and 22 mm, or larger than 22 mm were interpreted as resistant, intermediate, or susceptible,
respectively. For clindamycin (2-µg disks), strains with a zone
diameter smaller than 16 mm or larger than 18 mm were considered
resistant or susceptible, respectively. The overall susceptibility to
these agents before and after the ban as well as for the major species
E. faecium and E. hirae are reported in Table 1.
A clear decrease in resistance of enterococci to erythromycin,
spiramycin, and clindamycin was visible at all levels in samples
obtained after the ban. A strong association was observed between
resistance to macrolides and resistance to tetracycline
(P < 0.0001 for chi-square test and 95% confidence
interval for odds ratios of 8.1 to 43.8 for spiramycin resistance,
3.4 to 16.1 for erythromycin resistance, and 2.1 to 16.5 for
clindamycin resistance). A decreasing trend was consequently also
visible for tetracycline resistance after the ban of AGPs (Table
1).
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.11.4193-4195.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Antimicrobial Growth Promoter Ban and Resistance to
Macrolides and Vancomycin in Enterococci from Pigs
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
TABLE 1.
Antimicrobial susceptibility of fecal enterococci from
pigs before and after the ban of AGPs
Four vancomycin-resistant E. faecium isolates (VRE) were
recovered from two farms during the present study. Three of them were
obtained from a single farm (two in the first fecal sample and one in
the second sample, obtained 224 days later). All four VRE isolates were
simultaneously resistant to penicillin, erythromycin, spiramycin,
clindamycin, and tetracycline. The presence of the vanA gene
in all four isolates was confirmed by PCR following the method of
Dutka-Malen and collaborators (7). One VRE isolate from
each of the two farms was examined for the presence of the ermB and tet(M) genes and transferability of
vancomycin resistance as previously described (1). Both
isolates contained the tet(M) and ermB genes, and
transfer of vancomycin resistance was associated with transfer of
erythromycin resistance but not tetracycline resistance. The four VRE
and four other epidemiologically unrelated E. faecium
isolates from four other pig farms were typed by pulsed-field gel
electrophoresis (PFGE). DNA plugs were prepared by standard procedures,
and the DNA was digested using the restriction enzyme SmaI.
The electrophoresis was done in SeaKem gold agarose (FMC Bioproducts,
Rockland, Maine) and 0.5× Tris-borate-EDTA at 12°C in a CHEF III
electrophoresis unit (Bio-Rad, Hercules, Calif.). An electrical field
of 6 V/cm with an angle of 120° and pulses ranging from 1 to 25 s was applied to the gel for a period of 16 h. The results
presented in Fig. 1A show that all three
VRE isolates from the same farm were identical (lanes 2 to 4) and clearly had more bands in common with the fourth VRE isolate of the
other farm (lane 1) than with vancomycin-susceptible isolates originating from unrelated farms (lanes 6 to 9). The PFGE profiles of
the VRE isolates found in the present study were compared to those of representative VRE from Danish pigs (1). Their
profiles shared many bands, and the profiles of the two Swiss VRE
isolates differed in only one to five bands from the profiles of the
Danish VRE isolates (Fig. 1B), thus showing that VRE from pigs in
Switzerland and in Denmark belong to the same E. faecium clonal lineage. A fourth E. faecium isolate was
recovered after the ban of AGPs in the Swiss farm where the three
VRE were found. Similarly to the three VRE, this isolate was resistant
to penicillin, erythromycin, spiramycin, clindamycin, and tetracycline
but not to vancomycin, and it lacked the vanA gene. The PFGE
profile of this particular vancomycin-susceptible isolate (Fig. 1A,
lane 5) presented clear similarities with the VRE isolates. Hence,
E. faecium isolates belonging to the particular clonal
lineage containing VRE isolates from Swiss and Danish pigs are not
systematically resistant to vancomycin.
|
Data on the evolution of antimicrobial resistance after discontinuation of AGP use are scarce (4). The present study suggests that the complete AGP ban applied in Switzerland had a relatively rapid effect on antimicrobial resistance in enterococci and support similar data obtained recently in Denmark (4). Resistance to macrolides and lincosamides drastically decreased shortly after the ban enforcement. In addition, a parallel decrease in tetracycline resistance was observed, which suggests that a ban on AGPs may also have positive effects on the susceptibility of enterococci to unrelated therapeutically important antimicrobial agents not used as AGPs (Table 1). These results strongly support the precautions taken by European countries in order to reduce the frequency of antimicrobial resistance in bacteria of general public health relevance from animals. Despite the avoparcin ban in 1997, VRE could still be isolated without the use of any vancomycin-containing selective culture media in Swiss pigs at the end of 1999. This finding suggests that VRE are still present at a significant level in Swiss pigs more than 2 years after the discontinuation of avoparcin use. A similar observation had been made with Danish pigs after the ban of avoparcin (4, 5). Because of the frequent presence of macrolide and glycopeptide resistance genes on the same genetic element in E. faecium isolates from pigs (1), this persistence may be due to a selection of VRE by other AGPs (tylosin was used as an AGP in Switzerland until June 1999). The recovery of the same VRE clone in the same farm at an interval of more than 7 months without any avoparcin selection but with initial tylosin use supports this hypothesis. One can therefore hope that the total ban of all AGPs enforced in Switzerland and in some other European countries may be a more effective measure in reducing the frequency of VRE and multiresistant enterococci in general in the animal reservoir than a ban of only selected AGPs.
Interestingly, the VRE isolates found in Swiss pigs in the course of the present study belonged to the same broad E. faecium clonal lineage as VRE from Danish pigs. A comparison with epidemiologically unrelated vancomycin-susceptible isolates shows that the observed similarities between Swiss and Danish VRE is not due to a lack of discrimination among E. faecium isolates from pigs but is indicative of a true genetic and probably epidemiological relatedness. Therefore, the present report suggests that, as in the case of the multiresistant clone of Salmonella enterica serovar Typhimurium phage type DT104, a broad VRE clone apparently associated with pigs (1) has spread among pigs in different countries and may be widely distributed in Europe. The epidemiology of antimicrobial resistance in commensal bacteria from the animal reservoir and the effects of the use of AGPs should therefore be examined not only at the local level but also at a more global and international level. Finally, the exact reasons for the apparent confinement of the vancomycin resistance determinants to this single E. faecium clonal lineage in pigs despite their documented transferability (1) remain to be elucidated.
| |
ACKNOWLEDGMENTS |
|---|
We are very grateful to L. Fawer for her excellent technical assistance in this project.
This work was supported by a grant from the Swiss Veterinary Office.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Institute for Veterinary Bacteriology, Länggass-Strasse 122, 3012 Bern, Switzerland. Phone: (41) 31 631 2368. Fax: (41) 31 631 2634. E-mail: patrick.boerlin{at}vbi.unibe.ch.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Aarestrup, F. M.
2000.
Characterization of glycopeptide-resistant Enterococcus faecium (GRE) from broilers and pigs in Denmark: genetic evidence that persistence of GRE in pig herds is associated with coselection by resistance to macrolides.
J. Clin. Microbiol.
38:2774-2777 |
| 2. | Aarestrup, F. M., and B. Cartensen. 1998. Effect of tylosin used as a growth promoter on the occurrence of macrolide resistant enterococci and staphylococci in pigs. Microb. Drug Resist. 4:307-312[Medline]. |
| 3. | Aarestrup, F. M., H. Kruse, E. Tast, A. M. Hammerum, and L. B. Jensen. 2000. Association between the use of antimicrobial agents for growth promotion and the occurrence of resistance among Enterococcus faecium from broilers and pigs in Denmark, Finland, and Norway. Microb. Drug Resist. 6:63-70[Medline]. |
| 4. |
Aarestrup, F. M.,
A. M. Seyfarth,
H.-D. Emborg,
K. Pedersen,
R. S. Hendriksen, and F. Bager.
2001.
Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark.
Antimicrob. Agents Chemother.
45:2054-2059 |
| 5. | Bager, F., F. M. Aarestrup, M. Madsen, and H. C. Wegener. 1999. Glycopeptide resistance in Enterococcus faecium from broilers and pigs following discontinued use of avoparcin. Microb. Drug Resist. 5:53-56[Medline]. |
| 6. | Bager, F., M. Madsen, J. Christensen, and F. M. Aarestrup. 1997. Avoparcin used as a growth promoter is associated with the occurrence of vancomycin-resistant Enterococcus faecium on Danish poultry and pig farms. Prev. Vet. Med. 31:95-112[CrossRef][Medline]. |
| 7. | Dutka-Malen, S., S. Evers, and P. Courvalin. 1995. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J. Clin. Microbiol. 33:24-27[Abstract]. |
| 8. | Klare, I., H. Heier, H. Claus, R. Reissbrodt, and W. Witte. 1995. vanA-mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry. FEMS Microbiol. Lett. 125:165-171[CrossRef][Medline]. |
| 9. | National Committee for Clinical Laboratory Standards. 2000. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A7, 7th ed., vol. 20, no. 1. National Committee for Clinical Laboratory Standards, Wayne, Pa. |
| 10. | National Committee for Clinical Laboratory Standards. 2000. Disk diffusion, supplemental tables. M100-S10 (M2). National Committee for Clinical Laboratory Standards, Wayne, Pa. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»